1. Home
  2. BWG vs RFL Comparison

BWG vs RFL Comparison

Compare BWG & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BrandywineGLOBAL Global Income Opportunities Fund Inc.

BWG

BrandywineGLOBAL Global Income Opportunities Fund Inc.

SELL

Current Price

$6.88

Market Cap

134.7M

Sector

Finance

ML Signal

SELL

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.43

Market Cap

133.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWG
RFL
Founded
2012
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Real Estate
Sector
Finance
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
134.7M
133.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
BWG
RFL
Price
$6.88
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
126.2K
★ 150.1K
Earning Date
01-01-0001
10-28-2026
Dividend Yield
★ 11.37%
N/A
EPS Growth
N/A
★ 28.28
EPS
★ N/A
N/A
Revenue
N/A
★ $917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 43.96
52 Week Low
$6.76
$1.12
52 Week High
$8.71
$3.96

Technical Indicators

Market Signals
Indicator
BWG
RFL
Relative Strength Index (RSI) 30.71 33.00
Support Level N/A $1.24
Resistance Level $8.07 $1.58
Average True Range (ATR) 0.12 0.14
MACD 0.02 -0.01
Stochastic Oscillator 41.83 15.79

Price Performance

Historical Comparison
BWG
RFL

About BWG BrandywineGLOBAL Global Income Opportunities Fund Inc.

BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: